Chaudhary Zuraiz's Form 4 filing
Turn Therapeutics Inc. (TTRX) · filed Nov 17, 2025
- Accession no.
- 0001213900-25-111713
- Filed
- Nov 17, 2025
- Trade date
- Nov 17, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $9.05K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chaudhary ZuraizCIK 0002086494 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | Common Stock | PPurchaseAcquired | +2,500 | $3.62F1 | +$9,050 | 7,550 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.69, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer.